Nicolas Moniotte

Title: Nicolas Moniotte: Innovator in Vaccine Composition

Introduction

Nicolas Moniotte is a notable inventor based in Rockville, MD (US). He has made significant contributions to the field of vaccine formulations, particularly through his innovative patents. With a total of 3 patents, Moniotte's work focuses on enhancing the efficacy and stability of vaccine compositions.

Latest Patents

Moniotte's latest patents include a dried composition of saponin in a liposomal formulation with a neutral lipid, a sterol, and a cryoprotectant. This composition is designed to be dried under reduced pressure from a liquid mixture that includes an adjuvant comprising a saponin, such as QS21, in a liposomal formulation. The liposomes contain a neutral lipid, like phosphatidylcholine, and a sterol, such as cholesterol, along with a cryoprotectant that is an amorphous sugar. The adjuvant may also include a TLR-4 agonist, and the compositions can further comprise an antigen derived from HIV, ntHi, or Varicella Zoster Virus. Another patent describes a dried saponin liposomal composition that formulates immunogenic or vaccine compositions suitable for lyophilization, ensuring that both the immunogen and the adjuvant are present in the same vial.

Career Highlights

Nicolas Moniotte is currently associated with GlaxoSmithKline Biologicals SA, where he continues to advance research in vaccine development. His work has been instrumental in creating formulations that improve the stability and effectiveness of vaccines.

Collaborations

Moniotte collaborates with Dominique Ingrid Lemoine, contributing to the innovative research and development of vaccine technologies.

Conclusion

Nicolas Moniotte's contributions to vaccine formulation through his patents highlight his role as a key innovator in the field. His work continues to impact the development of effective immunogenic compositions.